SCHEMBL2652333

SCHEMBL2652333

CCOCCN1CCN(c2cccc(-n3cnc4cc(C(=O)O)ccc43)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.54
KMT2A Q03164 2/20 0.53
HPGD P15428 10/20 0.48
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
HCAR3 P49019 1/20 0.48
THRB P10828 1/20 0.47
NPC1 O15118 2/20 0.46
MEN1 O00255 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GLA P06280 1/20 0.46
RAB9A P51151 1/20 0.46
SRC P12931 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653965 0.91 FGFR1 (0.56) FGFR1KMT2AHPGDALDH1A1LMNA
SCHEMBL5781795 0.89 FGFR1 (0.54) FGFR1HPGDALDH1A1LMNATHRB
SCHEMBL2653620 0.88 KMT2A (0.49) FGFR1KMT2AHPGDNPC1MEN1
SCHEMBL2653245 0.88 KMT2A (0.51) FGFR1KMT2AHPGDALDH1A1NPC1
SCHEMBL5782569 0.87 FGFR1 (0.61) FGFR1HPGDALDH1A1LMNATHRB
SCHEMBL4701541 0.87 KMT2A (0.48) FGFR1KMT2AHPGDALDH1A1NPC1
SCHEMBL5780808 0.86 FGFR1 (0.60) FGFR1HPGDALDH1A1LMNATHRB
SCHEMBL2654163 0.86 KMT2A (0.47) FGFR1KMT2AHPGDALDH1A1NPC1
SCHEMBL2652876 0.86 KMT2A (0.49) FGFR1KMT2AHPGDALDH1A1NPC1
SCHEMBL5781363 0.85 FGFR1 (0.54) FGFR1KMT2AHPGDALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615896-B1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH AS (DK) 2008-04-23 EP claimed
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUSEARCH A/S (DK) 2006-10-26 US claimed
EP-1615896-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2006-01-18 EP claimed
WO-2004089912-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2004-10-21 WO claimed
EP-1615896-B1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH AS (DK) 2008-04-23 EP disclosed
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUSEARCH A/S (DK) 2006-10-26 US disclosed
EP-1615896-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2006-01-18 EP disclosed
WO-2004089912-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241101-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds GABRA2, GABRA1, GABRA5 FGFR1 2849/4885KMT2A 2056/4885HPGD 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.